MARKUS KRAMBERG,MARKUS REY,MARKUS RIEDERER,MARTINE BAUMANN,SEBASTIEN ROUX
申请号：
BR112019014567
公开号：
BR112019014567A2
申请日:
2018.03.14
申请国别(地区):
BR
年份:
2020
代理人:
摘要：
the present invention relates to a p2y12 receptor antagonist selected from the group consisting of 4 - ((r) -2 - {[6 - ((s) -3-methoxy-pyrrolidin-1-yl) - butyl ester 2-phenyl-pyrimidine-4-carbonyl] -amino} -3-phosphono-propionyl) -piperazine-1-carboxylic, (1s, 2s, 3r, 5s) -3- [7 - [(1r, 2s) -2 - (3,4-difluorophenyl) cyclopropylamino] -5- (propylthio) -3h- [1,2,3] triazolo [4,5-d] pyrimidin-3-yl] -5- (2-hydroxyethoxy) cyclopentane- 1,2-diol, and (1s, 2r, 3s, 4r) -4- [7 - [(1r, 2s) -2- (3,4-difluorophenyl) cyclopropylamino] -5- (propylthio) -3h- [ 1,2,3] -triazolo [4,5-d] pyrimidin-3-yl] cyclopentane-1,2,3-triol, or a pharmaceutically acceptable salt thereof, for use as a medicine by subcutaneous or intradermal administration .a presente invenção refere-se a um antagonista do receptor p2y12 selecionado do grupo consistindo de éster butílico do ácido 4-((r)-2-{[6-((s)-3-metóxi-pirrolidin-1-il)-2-fenil-pirimidino-4-carbonil]-amino}-3-fosfono-propionil)-piperazino-1-carboxílico, (1s,2s,3r,5s)-3-[7-[(1r,2s)-2-(3,4-difluorofenil)ciclopropilamino]-5-(propiltio)-3h-[1,2,3]triazolo[4,5-d]pirimidin-3-il]-5-(2-hidroxietóxi)ciclopentano-1,2-diol, e (1s,2r,3s,4r)-4-[7-[(1r,2s)-2-(3,4-difluorofenil)ciclopropilamino]-5-(propiltio)-3h-[1,2,3]-triazolo[4,5-d]pirimidin-3-il]ciclopentano-1,2,3-triol, ou um sal farmaceuticamente aceitável do mesmo, para o uso como um medicamento pela administração subcutânea ou intradérmica.
